Literature DB >> 33922415

Off-Label Use of COVID-19 Vaccines from Ethical Issues to Medico-Legal Aspects: An Italian Perspective.

Davide Ferorelli1, Lorenzo Spagnolo1, Maricla Marrone1, Serena Corradi1, Maria Silvestre1, Federica Misceo1, Francesco Paolo Bianchi2, Pasquale Stefanizzi2, Biagio Solarino1, Alessandro Dell'Erba1, Silvio Tafuri2.   

Abstract

During the COVID-19 outbreak, the lack of official recommendations on the treatment has led healthcare workers to use multiple drugs not specifically tested and approved for the new insidious disease. After the availability of the first COVID-19 vaccines (Comirnaty Pfizer-BioNTech and Moderna COVID19 vaccine), an authorization was issued by national and international Drug Regulatory Agencies in order to speed up their introduction on the market and their administration on a large scale. Despite the authorization, the off-label use of these vaccines may still be possible especially to answer specific concerns as the lack of vaccine doses, the delay in the delivery of planned doses or the pressure from public opinion and political influence also in relation to the evolution of the pandemic. This paper aims to assess the possible off-label use of COVID-19 vaccines and the ethical and medico-legal implications of this eventuality. The scope of this paper is to point out the possible consequences of off-label use of COVID-19 vaccines and possible mitigation and preventive measures to be taken by healthcare workers involved in vaccination procedures.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; ethics; forensic sciences; off-label use; public health; safety of vaccines; vaccine; vaccine strategies

Year:  2021        PMID: 33922415     DOI: 10.3390/vaccines9050423

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  16 in total

1.  Possible solutions for barriers in incident reporting by residents.

Authors:  Kartinie Martowirono; José D Jansma; Scheltus J van Luijk; Cordula Wagner; A Bart Bijnen
Journal:  J Eval Clin Pract       Date:  2010-10-25       Impact factor: 2.431

2.  Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study.

Authors:  Laura Cuzzolin; Rocco Agostino
Journal:  Eur J Clin Pharmacol       Date:  2016-01       Impact factor: 2.953

3.  Post-marketing studies of drug efficacy: why?

Authors:  B L Strom; K L Melmon; O S Miettinen
Journal:  Am J Med       Date:  1985-03       Impact factor: 4.965

4.  Communicating Effectively About Emergency Use Authorization and Vaccines in the COVID-19 Pandemic.

Authors:  Sandra Crouse Quinn; Amelia M Jamison; Vicki Freimuth
Journal:  Am J Public Health       Date:  2020-11-25       Impact factor: 9.308

Review 5.  Off-label drug use in oncology: a systematic review of literature.

Authors:  M M Saiyed; P S Ong; L Chew
Journal:  J Clin Pharm Ther       Date:  2017-02-05       Impact factor: 2.512

6.  Off-label prescribing: a call for heightened professional and government oversight.

Authors:  Rebecca Dresser; Joel Frader
Journal:  J Law Med Ethics       Date:  2009       Impact factor: 1.718

Review 7.  Off-label use of vaccines.

Authors:  Pieter Neels; James Southern; Jon Abramson; Philippe Duclos; Joachim Hombach; Melanie Marti; Alanna Fitzgerald-Husek; Jacqueline Fournier-Caruana; Germaine Hanquet
Journal:  Vaccine       Date:  2017-03-22       Impact factor: 3.641

8.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Authors:  Jennifer M Dan; Jose Mateus; Yu Kato; Kathryn M Hastie; Esther Dawen Yu; Caterina E Faliti; Alba Grifoni; Sydney I Ramirez; Sonya Haupt; April Frazier; Catherine Nakao; Vamseedhar Rayaprolu; Stephen A Rawlings; Bjoern Peters; Florian Krammer; Viviana Simon; Erica Ollmann Saphire; Davey M Smith; Daniela Weiskopf; Alessandro Sette; Shane Crotty
Journal:  Science       Date:  2021-01-06       Impact factor: 47.728

9.  Ethical Challenges in Health Care Policy during COVID-19 Pandemic in Italy.

Authors:  Davide Ferorelli; Gabriele Mandarelli; Biagio Solarino
Journal:  Medicina (Kaunas)       Date:  2020-12-11       Impact factor: 2.430

10.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.

Authors:  Sheila F Lumley; Denise O'Donnell; Nicole E Stoesser; Philippa C Matthews; Alison Howarth; Stephanie B Hatch; Brian D Marsden; Stuart Cox; Tim James; Fiona Warren; Liam J Peck; Thomas G Ritter; Zoe de Toledo; Laura Warren; David Axten; Richard J Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Meera Chand; Derrick W Crook; Anne-Marie O'Donnell; Christopher P Conlon; Koen B Pouwels; A Sarah Walker; Tim E A Peto; Susan Hopkins; Timothy M Walker; Katie Jeffery; David W Eyre
Journal:  N Engl J Med       Date:  2020-12-23       Impact factor: 91.245

View more
  1 in total

1.  Little patients, large risks: An overview on patient safety management in pediatrics settings.

Authors:  Simona Nicolì; Marcello Benevento; Davide Ferorelli; Gabriele Mandarelli; Biagio Solarino
Journal:  Front Pediatr       Date:  2022-09-16       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.